2 news items
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CHRS
9 May 24
, consistent with our overarching mission to become a sustainable and growing oncology company improving outcomes for cancer patients
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
CHRS
13 Mar 24
of FDA-approved products and a promising immuno-oncology pipeline, we are now better positioned than ever to execute on our mission of extending
- Prev
- 1
- Next